The Cancer News
https://binaytara.org/cancernewsAn authoritative, independent resource bringing expert analysis in oncology to clinicians, researchers, and patients. Covering clinical breakthroughs, treatment advances, cancer education, health policy, and global oncology. A publication of Binaytara.
Entries
-
Compare nonhormonal options like fezolinetant and elinzanetant for managing hot flashes and sleep disruption in breas...
-
Discover how distance, income, and insurance access shape which lymphoma patients actually receive CAR T-cell therapy...
-
NRG-GY019 confirms chemotherapy plus letrozole as frontline care for low-grade serous ovarian cancer, while new targe...
-
Review ADCs in lung cancer: approved HER2, cMET, and TROP2 agents in NSCLC, emerging SCLC options, and managing pneum...
-
Review ADCs in lung cancer: approved HER2, cMET, and TROP2 agents in NSCLC, emerging SCLC options, and managing pneum...
-
Cancer can change sexual health, but help exists. Oncology experts explain common changes, safe treatments like vagin...
-
Cancer can change sexual health, but help exists. Oncology experts explain common changes, safe treatments like vagin...
-
Explore the evidence behind adjuvant therapy, first-line selection, and treatment sequencing for kidney cancer, inclu...
-
CAR-T, Bispecifics, or Transplant: Sequencing Relapsed Diffuse Large B-Cell Lymphoma Therapy in 2026
Relapsed DLBCL treatment now centers on CAR-T eligibility, with bispecific antibodies like mosunetuzumab-polatuzumab ...
-
Compare CAR-T and bispecific antibody combinations for primary refractory DLBCL, including ZUMA-7, TRANSFORM, STARGLO...
-
Review SCLC in 2026: ADRIATIC consolidation durvalumab, tarlatamab full approval, IMforte lurbinectedin maintenance, ...
-
MATTERHORN and NeoSUMMIT-01 make perioperative immunotherapy standard in gastric/GEJ cancer, while zanidatamab advanc...
-
A case of severe niraparib-induced thrombocytopenia in BRCA1-mutated ovarian cancer shows how to weigh PARP inhibitor...
-
Why does milk thistle carry a cancer warning? Learn what the Prop 65 label means, plus estrogen concerns for hormone-...
-
Learn how centers manage cytokine release syndrome after CAR-T and bispecific therapy, from outpatient monitoring to ...
-
Learn how prior authorization and specialty pharmacy steering delay oral chemotherapy, add financial toxicity, and ho...
-
Learn how timing of relapse shapes post-CAR-T treatment in large B-cell lymphoma, from CD20 bispecific combinations t...
-
See how CAR T-cell therapy, bispecific antibodies, and antibody-drug conjugates are reshaping treatment sequencing fo...
-
Explore the expanding oral SERD landscape and how ctDNA-guided treatment switching before progression is changing HR-...
-
Learn the structured monitoring schedule for capivasertib-associated hyperglycemia and when home glucometer use can h...